Back to User profile » Dr Xuelei Ma
Papers published by Dr Xuelei Ma:
Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools
Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J, Ma X
International Journal of Nanomedicine 2024, 19:13615-13651
Published Date: 19 December 2024
Nanomedicines Targeting Tumor Cells or Tumor-Associated Macrophages for Combinatorial Cancer Photodynamic Therapy and Immunotherapy: Strategies and Influencing Factors
Wei Y, Li R, Wang Y, Fu J, Liu J, Ma X
International Journal of Nanomedicine 2024, 19:10129-10144
Published Date: 4 October 2024
The Prognostic Value of Inflammation Factors in Hepatocellular Carcinoma Patients with Hepatic Artery Interventional Treatments: A Retrospective Study
Guo L, Ren H, Pu L, Zhu X, Liu Y, Ma X
Cancer Management and Research 2020, 12:7173-7188
Published Date: 13 August 2020
The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
Wang M, Wu S, Tong A, Cui X, Ma X
Cancer Management and Research 2019, 11:7981-7989
Published Date: 22 August 2019
Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study
Guo L, Ren H, Zeng H, Gong Y, Ma X
OncoTargets and Therapy 2019, 12:3859-3868
Published Date: 17 May 2019
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X
Drug Design, Development and Therapy 2018, 12:2085-2096
Published Date: 6 July 2018
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
Zhang J, Li J, Zhu C, Song Y, Xia F, Ma X
Drug Design, Development and Therapy 2017, 11:3235-3244
Published Date: 15 November 2017
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Wang MN, Ma XL, Guo LH, Xia F
Drug Design, Development and Therapy 2017, 11:2851-2860
Published Date: 27 September 2017